Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

SA Transcripts159.33K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Unicycive Therapeutics, Inc. (UNCY) 25th Annual Needham Virtual Healthcare Conference April 15, 2026 3:45 PM EDT Company Participants Shalabh Gupta - Founder, Chairman, CEO & President Conference Call Participants Serge Belanger - Needham & Company, LLC, Research Division Presentation Serge BelangerNeedham & Company, LLC, Research Division Good afternoon. Welcome to Needham's 25th Annual Healthcare Conference. I'm Serge Belanger, one of the health care analysts at Needham. For our next session, I'd like to welcome Unicycive Therapeutics, a company developing therapies for kidney diseases. And from the company, we have the CEO, Shalabh Gupta, who is going to tell us about Unicycive. They have an important PDUFA coming up in a couple of months here. I think that will be a big focus. So I'll hand it over to Shalabh, and he can talk to us about Unicycive, and then we'll follow up with a Q&A session after the presentation. Shalabh, welcome. Shalabh GuptaFounder, Chairman, CEO & President Thank you. Thank you to the Needham team, and thank you, Serge, for giving me this opportunity. It's great to speak with all of you. Thank you so much. I'll be making forward-looking statements. So please read them before making investment decisions. By way of background, we are a clinical-stage biotechnology company based in Silicon Valley, California. And Serge, as you mentioned, we have a very near-term upcoming catalyst, which is a PDUFA date for our lead drug, which is oxylanthanum carbonate. And it is indicated for patients who suffer from hyperphosphatemia, a condition happens to patients as they are on dialysis and they have high phosphate. We have focused our entire energy at the moment on our lead drug, which is the OLC. We have a second drug also called UNI-494, which has completed Phase I clinical trial, is indicated for